The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index; 46 of the 149 sources its claims cite were checked for support.
Triple Agonism Based Therapies for Obesity
Open accessAbstract
Purpose of the Review: Glucagon-like peptide 1 (GLP-1) receptor agonists (RA) have transformed obesity and type 2 diabetes (T2D) management. Tirzepatide, the first dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) RA approved for both conditions, has paved the way for next-generation incretin-based therapies. Among these, triple agonists targeting GLP-1, GIP, and glucagon receptors represent a promising next step. This review outlines the rationale for their development and summarizes clinical trial data, focusing on retatrutide, the most advanced candidate. Recent Findings: Retatrutide is the first triple agonist (acting on GLP-1/GIP/glucagon receptors) with published phase 2 data in people with obesity as well as in people with T2D. Retatrutide achieved up to 24.2% mean weight loss after 48 weeks in individuals with obesity and 16.9% in those with T2D after 36 weeks. In the T2D study, HbA1c improved by 2.2%, with 82% of participants reaching HbA1c ≤ 6.5%. Retatrutide also improved multiple cardiometabolic parameters, including blood pressure, lipids, waist circumference, and liver fat (82% reduction in hepatic steatosis). Gastrointestinal symptoms were the most common side effects; no major safety concerns were observed. A comprehensive phase 3 program is ongoing to evaluate efficacy, safety, and cardiovascular/renal outcomes in people with obesity and/or T2D. Other unimolecular triple agonists and combination regimens involving tirzepatide with additional mono agonists are also in development. Summary: Retatrutide, a triple agonist now in phase 3 trials, has the potential to become the most effective pharmacological treatment for obesity while also offering substantial benefits in T2D management and other cardiometabolic risk factors.
Overview
CoChat Summary
## TL;DR
This review argues that triple agonists targeting GLP-1/GIP/glucagon receptors are the next major step beyond tirzepatide for obesity and type 2 diabetes, with retatrutide the leading candidate. Phase 2 data reported up to 24.2% mean weight loss at 48 weeks in obesity and 16.9% at 36 weeks in type 2 diabetes, with generally GI-limited adverse effects and no major safety signal.
## Key findings
- In the obesity phase 2 trial, retatrutide 12 mg produced 24.2% mean weight loss at 48 weeks vs 2.1% with placebo; 64% vs 1% achieved ≥20% weight loss.
- In the type 2 diabetes phase 2 trial, retatrutide 12 mg produced 16.9% weight loss at 36 weeks vs 3.0% with placebo and 2.0% with dulaglutide 1.5 mg.
- In the type 2 diabetes trial, retatrutide 12 mg reduced HbA1c by 2.16% at 36 weeks; 77–82% of participants on retatrutide 8–12 mg achieved HbA1c ≤ 6.5%.
- Retatrutide improved other cardiometabolic outcomes, including waist circumference, lipids, blood pressure, and in a liver-fat substudy, hepatic steatosis fell by 82.4% with 12 mg at 24 weeks; 86% achieved healthy liver fat levels (<5%).
- The paper reports that adverse effects were mainly mild-to-moderate gastrointestinal symptoms; serious adverse events in phase 2 were 4% overall in the obesity trial and 4–8% across retatrutide arms in the type 2 diabetes trial.
## Methods
- Narrative review of completed and ongoing clinical trials of triple agonists for obesity, with emphasis on retatrutide as the most advanced agent.
- Summarizes phase 1, phase 1b, and two published phase 2 trials: one in 338 participants with obesity without T2D and one in 281 participants with T2D and overweight/obesity.
- Main analysis is descriptive synthesis of trial designs and outcomes, including weight loss, glycaemia, cardiometabolic markers, liver fat, kidney markers, and adverse events.
## Limitations
- The paper states that long-term safety, efficacy, and cardiovascular/renal outcomes are still awaited, and that cardiovascular outcome trials for multi-agonists have not yet been completed.
- The text makes evident that evidence is still early-stage and largely from phase 2 trials; this is an implication from the paper’s own framing of retatrutide as the lead candidate with ongoing phase 3 studies.
- The paper notes that head-to-head trials versus currently approved obesity treatments do not exist; this limits direct comparative conclusions.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


![Fig. 3 Weight loss with retatrutide as compared to currently licenced obesity pharmacotherapy. Data from: [8, 27, 45, 49, 46, 50]](https://figures.cochat.ai/paper-figures/48dcaf9cd27946989712f827eae30453/triple-agonism-based-therapies-for-obesity-figure-3.jpg)
![Fig. 4 Weight loss with retatrutide as compared to licenced obesity pharmacotherapies and upcoming dual agonists in phase 3 trials in people with obesity and with type 2 diabetes. GIP: Glucose-dependent insulinotropic polypeptide; GLP-1: Glucagon-like peptide 1; GCG: Glucagon; RA: Receptor agonist; qw: once weekly dosing; biw: twice weekly dosing. Data from: [45, 50, 27, 8, 46, 49, 51, 35, 52, 36, 53]](https://figures.cochat.ai/paper-figures/2cfc34954c8444398d00e9cfde81b40d/triple-agonism-based-therapies-for-obesity-figure-4.jpg)
Verification
Claims the paper makes
35 Valid · 1 Not valid · 65 Not checked · 7 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“with preclinical and early-phase clinical trials supporting their potential as next-generation obesity treatments [16–23].”
§ Triple Agonism Based Therapies for Obesity > Introduction
What the sources say
- Not checked — no full text of the sourcecites [16] Nørregaard PK, Deryabina MA, Tofteng Shelton P, Fog JU, Daugaard JR, Eriksson PO, et al. A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents. Diabetes Obes Metab. 2018;20(1):60–8. source
- Not checked — no full text of the sourcecites [17] Cegla J, Troke RC, Jones B, Tharakan G, Kenkre J, McCullough KA, et al. Coinfusion of low-dose GLP-1 and glucagon in man results in a reduction in food intake. Diabetes. 2014;63(11):3711–20. source
- Partly supportedcites [18] Pocai A, Carrington PE, Adams JR, Wright M, Eiermann G, Zhu L, et al. Glucagon-Like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes. 2009;58(10):2258–66. sourceExperimental — accuracy not yet measured
The Results and Discussion (page numbers unavailable) support the potential of GLP-1/glucagon dual agonism as an obesity treatment based on experiments in mice. The paper does not study triple agonists or report an early-phase clinical trial of its dual agonist; the Discussion says whether its effects in rodents predict clinical effects remains to be determined. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [19] NamKoong C, Kim MS, Jang BT, Lee YH, Cho YM, Choi HJ. Central administration of GLP-1 and GIP decreases feeding in mice. Biochem Biophys Res Commun. 2017;490(2):247–52. source
- Not checked — no full text of the sourcecites [20] Finan B, Ma T, Ottaway N, Müller TD, Habegger KM, Heppner KM, et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med. 2013;5(209):209ra151. source
- Partly supportedcites [21] Karagiannis T, Malandris K, Avgerinos I, Stamati A, Kakotrichi P, Liakos A, et al. Subcutaneously administered Tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. Diabetologia. 2024;67(7):1206–22. sourceExperimental — accuracy not yet measured
The Introduction identifies tirzepatide as a dual agonist and reports weight loss in people with type 2 diabetes; the Discussion describes its potential for weight management. The paper does not address triple agonists or preclinical evidence, and its cited early-phase trial concerns type 2 diabetes rather than obesity treatment. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [22] Finan B, Yang B, Ottaway N, Smiley DL, Ma T, Clemmensen C, et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med. 2015;21(1):27–36. source
- Partly supportedcites [23] Jall S, Sachs S, Clemmensen C, Finan B, Neff F, DiMarchi RD, et al. Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice. Mol Metab. 2017;6(5):440–6. sourceExperimental — accuracy not yet measured
The Results and Conclusion (pages not provided) report that GLP-1/GIP/glucagon triple agonism reduced body weight in obese mice and suggest its potential as an obesity treatment. This supports the preclinical triple-agonist portion of the claim, but the paper does not report early-phase clinical trials or establish the potential of dual agonists. (LLM, conf=0.89)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Looking for the next step in obesity pharmacotherapies, the concept of combining entero-pancreatic hormones for obesity treatment was supported by the marked WL, sustained weight maintenance, and metabolic benefits observed with BS, which increase multiple gut hormone levels [9–14].”
§ Triple Agonism Based Therapies for Obesity > Introduction
What the sources say
- Not checked — no full text of the sourcecites [9] Akalestou E, Miras AD, Rutter GA, le Roux CW. Mechanisms of weight loss after obesity surgery. Endocr Rev. 2022;43(1):19–34. source
- Not checked — no full text of the sourcecites [10] Svane MS, Jørgensen NB, Bojsen-Møller KN, Dirksen C, Nielsen S, Kristiansen VB, et al. Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery. Int J Obes (Lond). 2016;40(11):1699–706. source
- Partly supportedcites [11] le Roux CW, Aylwin SJB, Batterham RL, Borg CM, Coyle F, Prasad V, et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg. 2006;243(1):108–14. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Not checked — no full text of the sourcecites [12] Nielsen MS, Ritz C, Wewer Albrechtsen NJ, Holst JJ, le Roux CW, Sjödin A. Oxyntomodulin and Glicentin May predict the effect of bariatric surgery on food preferences and weight loss. J Clin Endocrinol Metab. 2020;105(4):dgaa061. source
- Not checked — no full text of the sourcecites [13] Perakakis N, Kokkinos A, Peradze N, Tentolouris N, Ghaly W, Pilitsi E, et al. Circulating levels of Gastrointestinal hormones in response to the most common types of bariatric surgery and predictive value for weight loss over one year: evidence from two independent trials. Metabolism. 2019;101:153997. source
- Partly supportedcites [14] Albaugh VL, Banan B, Ajouz H, Abumrad NN, Flynn CR. Bile acids and bariatric surgery. Mol Aspects Med. 2017;56:75–89. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Retatrutide is the first triple agonist (acting on GLP-1/GIP/glucagon receptors) with published phase 2 data in people with obesity as well as in people with T2D.”
§ Triple Agonism Based Therapies for Obesity > Abstract > Recent Findings
What the sources say
- Could not verifycites [45] Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, et al. Triple–Hormone-Receptor agonist Retatrutide for Obesity — A phase 2 trial. N Engl J Med. 2023;389(6):514–26. sourceExperimental — accuracy not yet measured
The cited Jastreboff et al. paper is a phase 2 obesity trial, but neither paper-scoped search returned text verifying the claim about published phase 2 data in people with type 2 diabetes. A separate review, “What is the pipeline for future medications for obesity?”, discusses both populations but cites different studies for the obesity and T2D trials. The exact sentence also appears in the review “Triple Agonism Based Therapies for Obesity” (unscoped score 1.0). Those matches show that the broader statement exists, not that this obesity trial alone supports all of it; they do not establish misattribution. (LLM, conf=0.74)
- Supportedcites [46] Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529–44. sourceExperimental — accuracy not yet measured
Rosenstock et al. (2023) is a phase 2 trial of retatrutide, a GIP/GLP-1/glucagon receptor agonist, in people with type 2 diabetes. A Semantic Scholar snippet from the review “Triple Agonism Based Therapies for Obesity” states the claim verbatim (score 1.0), and another snippet from that review lists the Rosenstock trial among its references (score 0.704). The obesity data come from a separate phase 2 trial, so the cited paper supports the diabetes half of this combined claim rather than documenting both populations on its own. (LLM, conf=0.78)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“To approach the efficacy of BS, dual and triple agonists combining GLP-1 with other entero-pancreatic hormones with complementary actions, including glucose-dependent insulinotropic polypeptide (GIP), glucagon (GCG) and amylin are currently under development [15].”
§ Triple Agonism Based Therapies for Obesity > Introduction
What the sources say
- Supportedcites [15] Melson E, Ashraf U, Papamargaritis D, Davies MJ. What is the pipeline for future medications for obesity? Int J Obes (Lond). 2024. source
The section on combinations of entero-pancreatic hormones says GIP, glucagon, and amylin are being investigated with GLP-1 to complement its effects, and links this approach to the weight-loss efficacy of bariatric surgery. The sections on dual GLP-1/amylin agonism and triple GLP-1/GIP/glucagon agonists describe ongoing clinical trials. No page numbers are available in our copy. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Furthermore, GIP inhibits hindbrain neurons regulating emesis [25]”
§ Triple Agonism Based Therapies for Obesity > Stepping-Stones Towards Triple Agonism: A Summary of GLP-1/GIP and GLP-1/GCG Dual-Agonist Development > GLP-1/GIP Dual Agonism
What the sources say
- Partly supportedcites [25] Borner T, Geisler CE, Fortin SM, Cosgrove R, Alsina-Fernandez J, Dogra M, et al. GIP receptor agonism attenuates GLP-1 receptor Agonist-Induced nausea and Emesis in preclinical models. Diabetes. 2021;70(11):2545–53. sourceExperimental — accuracy not yet measured
The Results section reports that GIPR agonist cotreatment reduced GLP-1R agonist–induced neuronal activation in the hindbrain AP/NTS and prevented emesis in shrews. The Discussion says local inhibitory neurons may mediate this effect, but presents that mechanism as a hypothesis; it does not establish that GIP directly inhibits emesis-regulating neurons generally. Page numbers are unavailable in our copy. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
55 more claims · 11 with their cited sources checked
Create a free account to see all 108 claims and every source verdict.
- Probably not a substantial claim. 9
- It may state two separate claims as one. 42
- The quote only partly states this claim. 1
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 2×
“…such evidence is available for retatrutide, therapies with established cardiovascular and renal benefits—such as semaglu - tide, supported by SUSTAIN-6 [5] and FLOW [57] trials in people with T2D, and the SELECT trial [58] in people with obesity - should be prioritised in populations with existing”
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 5×
“3) [8, 27, 45, 46, 49, 50].”
InfluentialSelf-citationEffects of Bariatric Surgery on Mortality in Swedish Obese Subjects
Sjöström, L., Narbro, K., Sjöström, C. D., Karason, K., Larsson, B., Wedel, H., Lystig, T., Sullivan, M., Bouchard, C., Carlsson, B., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066254 · Cited by 4,668
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 5×
“3) [8, 27, 45, 46, 49, 50].”
InfluentialSemaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170 · cited 1×
“GLP-1, a hormone primarily secreted from the ileum in response to nutrient intake, exerts multiple metabolic effects including appetite suppression, delayed gas - tric emptying, enhanced insulin secretion, and inhibition of glucagon release [4].”
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., Baeres, F. M. M., Idorn, T., Bosch-Traberg, H., Lausvig, N. L., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2403347 · Cited by 2,099 · cited 1×
“…such evidence is available for retatrutide, therapies with established cardiovascular and renal benefits—such as semaglu - tide, supported by SUSTAIN-6 [5] and FLOW [57] trials in people with T2D, and the SELECT trial [58] in people with obesity - should be prioritised in populations with existing”
Artificial intelligence to deep learning: machine intelligence approach for drug discovery
Gupta, R., Srivastava, D., Sahu, M., Tiwari, S., Ambasta, R. K., & Kumar, P. (2021) · Molecular Diversity · doi:10.1007/s11030-021-10217-3 · Cited by 1,473 · cited 1×
“Artificial Intelligence may allow for more accurate personalisation of therapy to predict the optimum ‘cocktail’ of mono agonist therapies based on the genetics and metabolomics of an individual and may quicken the process of drug development [70, 71].”
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419 · cited 3×
“Data from: [45, 50, 27, 8, 46, 49, 51, 35, 52, 36, 53] Current Cardiovascular Risk Reports (2025) 19:18 a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.”
Self-citation
Cited by
Ganamurali, N., & Sabarathinam, S. (2026) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.70001 · Cited by 8
Multimodal Prehabilitation for Hernia Repair: Linking Metabolic Modulation and Mechanical Methods
Păduraru, D. N., Palcău, A. C., Daniel, I., & Seicaru, R. (2025) · Biomedicines · doi:10.3390/biomedicines13123117 · Cited by 8
New and Emerging Therapeutic Targets for ApoB-Containing Particles Lowering
Gaudet, D., Larouche, M., Raal, F. J., & Catapano, A. L. (2026) · Circulation Research · doi:10.1161/circresaha.126.327270 · Cited by 5
Lempesis, I. G., & Dalamaga, Μ. (2026) · Metabolism Open · doi:10.1016/j.metop.2026.100463 · Cited by 8
Tentolouris, A., Siafarikas, C., Ntanasis‐Stathopoulos, I., Anastasiou, I. A., Kalara, E., & Briasoulis, Α. (2026) · Primary care diabetes · doi:10.1016/j.pcd.2026.01.003 · Cited by 2
Metadata
- Authors
- Goldney, J., Hamza, M., Surti, F., Davies, M. J., & Papamargaritis, D.
- Affiliations
- University of Leicester (GB)
- Corresponding author
- Papamargaritis, Dimitris
- Venue
- Current Cardiovascular Risk Reports
- Published
- 2025-07-28
- Volume
- 19
- Issue
- 1
- Pages
- 18-18
- ISSN
- 1932-9520 (ISSN-L)
- 1932-9563
- PMC
- PMC12304053
- OpenAlex
- W4412684430
- Semantic Scholar
- e47fa2dda82fe20aec55c09f45750a6fd66ee9f3
- Cited by
- 22
- References
- 66
- Citations by year
- 2026: 20 · 2025: 2
- FWCI
- 2.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Current Cardiovascular Risk Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Funders
- Wellcome Trust Leicestershire Healthcare Inequalities Improvement Doctoral Training Programme (223512/Z/21/Z)
- NIHR Leicester Biomedical Research Centre
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- obesity, type 2 diabetes, retatrutide, GLP-1 receptor agonists, GIP receptor agonist, glucagon receptor agonist, incretin-based therapy, weight loss, glycemic control, hepatic steatosis, cardiometabolic risk, gastrointestinal adverse effects
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Triple Agonism Based Therapies for Obesity. https://app.cochat.ai/papers/10.1007/s12170-025-00770-z
- The paper
- Goldney, J., Hamza, M., Surti, F., Davies, M. J., & Papamargaritis, D. (2025). Triple Agonism Based Therapies for Obesity. Current Cardiovascular Risk Reports. https://doi.org/10.1007/s12170-025-00770-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.